Abstract: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age. PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features. The effect of genetic variants in key metformin transporters, their transcriptional regulators or in metformin target genes on metformin response in women with PCOS is unclear. Associations between pharmacodynamic responses to metformin (changes in weight, lipid profile, insulin sensitivity evaluated by oral glucose tolerance testing) and polymorphisms in OCT1 (rs12208357 and rs72552763), HNF1A (rs1169288 and rs2464196), MATE1 (rs2289669 and rs2252281), MATE2-K (rs12943590) and ATM (rs11212617) were studied in 40 women with PCOS randomized to 12 months of treatment with metformin 1000 mg twice daily AE oral contraceptive pills (150 lg desogestrel + 30 lg ethinylestradiol). In the entire study population, treatment was associated with reduced weight (median weight change À2.4 kg, 25th-75th percentile À5.2 to 0.3 kg, p < 0.001) and increased triglycerides (0.2 mmol/L (0.0-0.6 mmol/L), p < 0.01) without significant changes in other lipid parameters or insulin sensitivity (insulin AUC , glucose AUC during OGTT). None of the evaluated polymorphisms significantly affected any treatment outcome. In conclusion, the genetic variants investigated were not crucial for the clinical response to metformin in PCOS.
Polycystic ovary syndrome (PCOS) affects 5-10% of premenopausal women [1] . Diagnostically defined by the presence of oligo/anovulation, hyperandrogenemia and/or detection of ovarian cysts, PCOS is characterized by broader metabolic features including obesity, dyslipidaemia and insulin resistance [2] . Metformin, best known as the first drug of choice for the treatment of type 2 diabetes (T2D) [3] , enhances insulin sensitivity, improves dyslipidaemia and has been shown, in PCOS, to specifically promote weight loss and increase frequency of ovulations [4] .
Metformin is a cation at physiological pH. Hence, the drug relies on distinct carrier proteins to mediate its absorption, hepatic uptake and renal excretion, including organic cation transporter 1 and 2 (OCT1 and OCT2) and multi-drug and toxin extrusion proteins 1 and 2-K (MATE1 and MATE2-K) [5] . OCT1 is well established as the primary mediator of hepatic uptake of metformin [6] , with this transporter's expression regulated by hepatocyte nuclear factor 1-alpha (HNF1A) [7] . OCT2, MATE1 and MATE2-K are located in the renal tubular cells and mediate metformin's urinal excretion [8, 9] .
Metformin is generally an efficacious, safe and low-cost drug, but interindividual variability with regard to the clinical efficacy is considerable, both in the setting of T2D [10] and PCOS [11] . It has been speculated that interindividual variation in metformin response may be founded in gene-treatment interactions [12] . Hence, polymorphisms in metformin transporter genes have been investigated as a potential mechanism accounting for such findings, particularly in T2D (e.g. [5, 13] ). Several OCT1 loss-of-function variants have been found to have reduced metformin transport in cellular assays, including those associated with the single nucleotide polymorphism (SNP) rs12208357 and the three bases deletion rs72552763 [14] . Shu et al. [14] reported ≥1 reduced-function OCT1 allele (including rs12208357 and rs72552763) to be associated with a significantly decreased acute glucose-lowering response to metformin after an oral glucose tolerance test (OGTT) in healthy volunteers. We have previously reported that in a large cohort of Danish patients with T2D, the number of reduced-function OCT1 alleles correlated with increased HbA1c levels after initiating of metformin treatment [5] ; however, when correcting for baseline HbA1c levels in a reanalysis, these findings were not confirmed [15] . The impact on metformin efficacy of OCT1-related transcription factor polymorphisms is largely unknown. As for renal metformin transporters, studies involving diabetic individuals have found the MATE1 alleles rs2289669/rs2252281 [16, 17] and the MATE2-K variant rs12943590 [17] to be associated with enhanced and reduced metformin response, respectively. On a non-transporter level, the first genomewide association study on metformin efficacy in T2D found the minor allele variant rs11212617 of ATM (the ataxia telangiectasia mutated gene, a putative upstream regulator of AMPK) to be associated with a superior response to metformin [18] .
When our current investigation was conceived, only one study in PCOS patients had previously examined the association between metformin efficacy and transporter gene polymorphisms. Gambineri et al. found carriers of a reducedfunction OCT1 polymorphism (e.g. rs12208357 and rs72552763) to have reduced response to metformin as assessed by changes in lipid profiles [19] . The study, in which treatment was limited to 6 months, did not examine genetic variants besides OCT1 putatively associated with metformin's efficacy [19] . In this study, we investigated whether PCOS patients randomized to 12-month treatment with metformin or metformin + oral contraceptive pills (OCP) had altered responses (primarily weight loss) to metformin in relation to carrier status for the OCT1 variants rs12208357 and rs72552763. For exploratory analysis, we also associated metformin responses with polymorphisms in MATE1 (rs2289669 and rs2252281), MATE2-K (rs12943590), ATM (rs11212617) and HNF1A (rs1169288 and rs2464196).
Material and Methods
Study design. The study design is described in a previous publication in which detailed information can be found [20] . In brief, included PCOS patients were randomized to 12-month treatment with metformin (1000 mg twice daily) alone or in combination with OCP (150 lg desogestrel + 30 lg ethinylestradiol). Patients randomized to OCP alone were not included in the present study. Changes from baseline in clinical and metabolic characteristics including responses during a 2-hr 75-g OGTT were measured after 12 months.
Study participants and ethics. Forty Caucasian women aged 18-39 years who met the Rotterdam criteria for PCOS [2] were enrolled in and completed the study (two metformin-treated subjects from our original paper [20] were not included in the current study due to insufficient quality and concentration of extracted DNA and due to missing blood sample, respectively). Additional endocrine diseases including diabetes or other serious co-morbidities were excluded based on clinical history and blood screening tests as previously detailed [20] . The study was approved by the local ethics committee and was performed in accordance with the Helsinki Declaration.
Selection of genetic variants. Genetic variants were selected from OCT1, MATE1, MATE2-K, HNF1A and ATM based on the following criteria: 1 The genetic variation had to be present in Caucasians. 2 Minor allele frequency >5%. 3 The genetic variation:
a Had to be located in or in near proximity of a gene coding for a transporter (OCT1) or a transcription factor (HNF1A) relevant for metformin's hepatic uptake or b Had repeatedly been reported in the literature to influence the outcome of metformin treatment in T2D (ATM, MATE1, MATE2-K, OCT1).
Genotyping. Genotypes were ascertained using TaqMan â predesigned assays or File-builder and conducted on a StepOne Plus from Applied Biosystems, Foster city, CA, USA, in accordance with the manufacturer's protocol. The assay numbers used for genotyping are summarized in Table S1 . The diplotypes of the two reduced-function alleles in OCT1 and the two SNPs in HNF1A were inferred using the software package PHASE (Stephens, University of Washington, Seattle, WA, USA), version 2.1.1. [21] .
Statistical analysis. Data are presented as medians with 25th-75th percentiles. A specific a priori sample-size calculation for this pharmacogenetic exploratory substudy was not performed. For OCT1, individuals were grouped according to their number of reducedfunction alleles, as the two polymorphisms investigated are considered functionally equivalent [14] . Statistical inferences of the pharmacodynamic results for the genotypes were analysed using oneway analysis of variance on log-transformed data to obtain normal distribution, adjusting for individual baseline values, glomerular filtration rates and treatment group (AE OCP). Groups with ≤3 subjects were withdrawn from the statistical analysis. A p-value < 0.05 was considered statistically significant. Excluding outcome related to OCT1 genotype, we adjusted for multiple testing via Bonferroni correction, multiplying the p-value by the number of independent tests. All statistical analyses were performed using STATA 11.0 (StataCorp, College Station, TX, USA).
Results
Baseline clinical and metabolic characteristics of study participants are presented in table 1. Minor allele frequencies were 0.21, 0.24, 0.33, 0.35, 0.38, 0.41 and 0.41 for rs12208357/ rs72552763 (OCT1), rs12943590 (MATE2-K), rs1169288 (HNF1A), rs2464196 (HNF1A), rs2252281 (MATE1), rs2289669 (MATE1) and rs11212617 (ATM), respectively.
For the entire study population, 12-month treatment with metformin AE OCP was associated with reductions in weight (À2.4 kg (À5.2 to 0.3 kg), p < 0.001) and an increase in triglycerides (0.2 mmol/L (0.0-0.6 mmol/L), p < 0.01) but did not significantly affect response to the OGTT (insulin AUC , 
ns À2.9 (À8.5, glucose AUC ) or other lipid parameters. There was no effect on treatment response of reduced-function OCT1 alleles or of any other evaluated genetic variant on these outcomes (table 2) . Likewise, none of the studied variants significantly impacted testosterone or SHBG responses to metformin (data not shown). The distribution of genotypes across intervention groups is shown in Table S2 .
Discussion
This study is the first to examine, in a randomized trial, the effects on metformin response in PCOS of genetic variations in key metformin transporters (OCT1, MATE1, MATE2-K), in an OCT1 transcriptional regulator (HNF1A) or in a metformin target gene (ATM). We found that none of the evaluated genetic variants significantly affected the clinical response to metformin (weight loss, lipid profile or insulin sensitivity evaluated by OGTT). When our present study was planned, only one publication had described the influence of OCT1 specifically on metformin response in PCOS. In a prospective study of 150 Italian PCOS patients treated with metformin 1000-2700 mg daily for 6 months, Gambineri et al. found that presence of one of four reduced-function OCT1 variants (including rs12208357/rs72552763) correlated with a reduced response to treatment as assessed by changes in total cholesterol and triglycerides [19] . While heterogeneity with respect to metformin dosing, study design and subject population tempers comparisons, the present study's discordant results regarding lipid profile responses to metformin underscore the importance of replication by independent research groups. Before our current study was published, Pau et al. became the second group to report the role of gene polymorphisms in clinical response to metformin in PCOS [22] . In the latter paper, changes in weight, fasting glucose, testosterone and ovulation were investigated in three ethnically diverse cohorts, namely a discovery cohort (n = 38) and two replication cohorts (n = 26 and n = 131) treated over 3-9 months with metformin 1500-2000 mg/day. Apart from the OCT1 variant rs683369 being associated with less weight loss in the discovery cohort but not in the replication studies, Pau et al. did not find polymorphisms of OCT1, OCT2, MATE1 or ATM to be associated with any metformin response (HNF1A, MATE2-K and lipid profiles were not investigated) [22] . We reproduce, in a strictly Caucasian patient population treated longer term with a fixed dose of metformin (2 g/day over 12 months), the finding that the noted genetic variants seemingly do not have an important effect on several relevant outcome parameters to metformin treatment in PCOS.
Our finding that metformin-related genetic variants have no major impact on treatment outcome is in agreement with some [15, 23] but not other [13, 17] studies involving patients with T2D. Of note, a very recent meta-analysis across several large-scale, genomewide studies reported no significant effect of polymorphisms in OCT1, OCT2, MATE1, MATE2-K or the metformin carnitine/cation transporter OCTN1 on glycaemic response to metformin in T2D as assessed by HbA1c changes Groups with ≤3 subjects were removed from the statistical analysis. [24] . The latter study, in particular, draws into question the currently established metformin-related genetic polymorphisms' influence on clinically observed variation in metformin treatment response, at least in T2D. Furthermore, a recent twin study in healthy volunteers [25] showed a weak heritability of metformin trough concentrations, indicating that metformin pharmacokinetics might not be as strongly genetically controlled as previously conceived.
The main strength of our study is the randomized, genotype-blinded nature of its design. Furthermore, 12-month treatment duration is sufficient to assess metformin's influence on weight loss [20] , a key metformin response outcome in PCOS [4] . The small sample size and the retrospective analysis are main weaknesses. In particular, the very limited number of homozygous OCT1, HNF1A and MATE2-K variant individuals (table 2) precludes a meaningful evaluation of these genotypes' effects on metformin response in PCOS. Furthermore, although the statistical inferences of the pharmacodynamic results for the various genotypes were adjusted for treatment group (i.e. metformin with or without OCP), the potential for confounding due to uneven distribution of certain genetic variants across the groups must nonetheless be acknowledged. Regarding our primary outcome parameter, limited long-term data are available concerning the effect of OCP on weight in PCOS. In 6-month studies, weight was unchanged in PCOS after treatment with OCP [26, 27] , and in the general population, a Cochrane review assessing 49 randomized, controlled trials did not find evidence supporting a causal association between OCP and weight gain [28] . However, it must be noted that for all subjects in the present study, weight loss after 12-month treatment was in fact greater in the metformin group compared to the metformin + OCP group [20] . As for lipid profiles, increases in HDL cholesterol and triglycerides in particular have consistently been found in PCOS after OCP treatment [29] . Studies of the actions of OCP on carbohydrate metabolism in PCOS have yielded more conflicting results [30] , with a meta-analysis indicating minimal effects [31] .
Recent data from our [24] and other [32] research groups indicate that the intestine may constitute metformin's main site of action [33] ; consequently, OGTT-related indices and plasma lipid profiles may represent less suited parameters for assessing clinical response to metformin. In future studies of PCOS, better candidates to correlate with metformin-related genetic variants might include, for example, gastrointestinal drug tolerance [34] .
